April 22, 2007 at 19:35:48

Secret AstraZeneca Audio Tapes: Violation of Corporate Integrity Agreement?

SAVE AS FAVORITE

VIEW FAVORITES

By Peter Rost (about the author) Page 1 of 2 page(s)

opednews.com Permalink

For OpEdNews: Peter Rost - Writer

An AstraZeneca anonymous whistleblower has just provided internal AstraZeneca training tapes (download below), which appear to indicate that AstraZeneca may be in violation of its Corporate Integrity Agreement with the Office of Inspector General of the United States Department of Health and Human Services. If such a violation is confirmed, it could in a worst case scenario result in exclusion of AstraZeneca from selling drugs to the Federal Government.

Here's the background:

AstraZeneca has been forced to sign a Corporate Integrity Agreement (CIA) with the OIG of HHS, based on past sins and violations. Among the many provisions of this CIA, AstraZeneca employees have to comply with AstraZeneca's own policies and procedures.

The AstraZeneca's policy for product promotion states that "As with all product discussions, all such product comparisons may be made only in the context of an objective, balanced presentation. The benefits of one product and the shortcomings of another may not be singled out."

The only way to make a balanced comparison between two products is to have a well designed, double-blind, randomized trial WITH THE TWO DRUGS IN THE SAME TRIAL.

But that doesn't seem to bother AstraZeneca; a company for which the lack of comparative trials is a mere nuisance, easily corrected with slick selling.

Proof of this, according to the AstraZeneca whistleblower, is two audio tracks from the "Arimidex/Faslodex," "Pharmaceutical Sales Specialist Objection Handler for the Tablet PC," which is a CD that was mailed to the AZ oncology sales force in January 2007.

Two of the audio tracks show exactly how to sell AZ's Arimidex against Novartis' letrozole (brand name FEMARA), by minimizing the efficacy message of letrozole, WITHOUT HAVING ANY COMPARATIVE DATA.

Click on the links below to download and listen to the drug company training conversations with a doctor:

Track 7 - Here a sales rep targets a physician who uses letrozole from Novartis. She gets the doc to talk about her use, then proceeds to minimize letrozole efficacy because Novartis used "sub-group analysis" that is "fraught with difficulty" and that the authors say "use caution when interpreting this analysis" in their BIG 1-98 trial.

Track 15 - Similar. Strategy is to generate a conversation about letrozole and then minimize the efficacy of letrozole in node positive patients by bashing the Novartis BIG 1-98 trial because of bad "sub group analysis".

SO HOW DOES THIS WORK? HOW CAN ASTRAZENECA USE NON-EXISTENT COMPARATIVE DATA TO DISS THE COMPETITION?

HERE's the deal:

1. AstraZeneca has an Arimidex versus tamoxifen study called ATAC.
2. Novartis has a letrozole versus tamoxifen study called BIG 1-98.
3. There are no studies of Arimidex versus letrozole.

Both training examples show exactly how oncology reps can:

1 | 2

Peter Rost M.D. Peter Rost, M.D., is a former Vice President of Pfizer. He is the author of "The Whistleblower, Confessions of a Healthcare Hitman" and "more...)

The views expressed in this article are the sole responsibility of the author
and do not necessarily reflect those of this website or its editors.